Dr. Wenqing Yang, CSO, Attends the Third World Cancer Research Conference (SWCR 2023) and Delivers a Compelling Presentation
2023-03-29
From March 27th to 29th, 2023, the Third World Cancer Research Conference (SWCR 2023) was held at the Grand Hyatt in Tokyo. The event featured 75 distinguished guest speakers from 22 countries around the world, including Dr. Karim Azer, Vice President of Axella Therapeutics from the USA; Mr. Stephan Baumann, Manager of the Infectious Disease Division at Agilent Technologies, USA; Dr. Qian H.Li, Vice President of Biostatistics and Consulting at SDC, USA; Dr. Olivier Pardo, Team Leader at Imperial College London, UK; and Dr. Michael Castro, a Neuro-Oncologist and Medical Oncologist from Personalized Cancer Medicine Inc., USA.
Dr. Wenqing Yang, CSO of our company, participated and organized the event as a member of the SWCR 2023 Scientific Committee. As a member of the Scientific Committee, Dr. Yang chaired the main scientific reporting meeting at the conference and delivered a keynote presentation in the plenary session.
SWCR 2023 hosted eight themed forums including "Immunotherapy and Nanomedicine," "Early Detection and Clinical Technologies," "Chemotherapy and Radiotherapy," "Tumor Microenvironment," "Leukemia and Lymphoma," "Cancer Biomarkers and Diagnostics," "Cancer Cell Biology," and "New Therapeutics and Treatments"; PSCR 2023 included five specialized sessions covering "Drug Design, Development, and Innovation," "Biomarkers and Diagnostics," "Legal, Regulatory, Policy and Market Trends," "Resistance and Vaccine Research," and "Cancer and Tumors."
During the conference, participants engaged in deep exchanges, shared experiences, and introduced new ideas and insights. The event provided an excellent platform for experts and scholars in the field of cancer research and drug discovery, helping to inspire research and find collaboration partners.
At the conference, Dr. Yang presented a plenary keynote titled “Rationalized therapy combining ICIs and antiangiogenic agents may hold great promise for cancer patients,” showcasing his expertise and authority. He offered new perspectives and deep insights for future cancer treatments. He discussed the potential of combining traditional radiotherapy with immune checkpoint inhibitors (ICIs), a novel approach that brings new hope for cancer treatment.
Dr. Yang emphasized that traditional chemoradiotherapy can effectively shrink tumors but also damages surrounding healthy tissues, causing severe side effects. In contrast, immune checkpoint inhibitors are a new type of immunotherapy that activates the patient's immune system to attack the tumor, offering great potential. He proposed that combining antiangiogenic targeted therapy with immune checkpoint inhibitors could maximize the advantages of both therapies, enhance treatment effects, and reduce side effects. He thoroughly explored the future direction of this combined therapy, including optimizing antiangiogenic and immunotherapy schedules, cleverly utilizing the complementary characteristics of both treatments, and enhancing the antitumor immune response of immune checkpoint inhibitors through targeted therapy.
Dr. Yang's keynote provided new thoughts and directions for future tumor treatments, bringing new hope to cancer patients. We look forward to this combined therapy being more widely and deeply applied in clinical practice, providing more effective treatment options for more cancer patients.
联科
Official Public Number
Copyright©2023 Nanjing Yunqiao Purui Biotechnology Co., Ltd.
